<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84181">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02134249</url>
  </required_header>
  <id_info>
    <org_study_id>khalid-ahmed</org_study_id>
    <nct_id>NCT02134249</nct_id>
  </id_info>
  <brief_title>Prevention of Ovarian Hyperstimulation Syndrome</brief_title>
  <acronym>infertility</acronym>
  <official_title>Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <authority>Egypt: Ministry of Higher Education</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of oral Diosmin to oral Cabergoline in
      the prevention of ovarian hyperstimulation syndrome (OHSS) in high-risk women underwent
      intracytoplasmic sperm injection (ICSI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two hundred women at risk of ovarian hyperstimulation syndrome during ICSI cycles will be
      randomly scheduled into two equal groups. In group A, (Diosmin group),  2 tab / 8 hs Diosmin
      ( 500mg) will be given  at  day of HCG injection and for 2 weeks ; while in group B
      (Cabergoline  group), 1 tab/day Cabergoline( 0.5 mg) will be given at  day of HCG injection
      and for 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>ovarian hyperstimulation syndrome (OHSS)</measure>
    <time_frame>every two weeks for eight weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>this will be assessed by:
Clinically:
Abdominal bloating
Mild abdominal pain
Nausea ± vomiting
Oliguria
Acute respiratory distress syndrome
By ultrasound
Ovarian size usually ˃8 cm
Ultrasound evidence of ascites
Laboratory
Haemoconcentration haematocrit ˃45%
Hypoproteinaemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>16 days after embryos transfer</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>β-hCG (serum hCG test) will be checked 16 days after embryos transfer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Group A (Diosmin group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In group A, (Diosmin group),  2 tab / 8 hs Diosmin ( 500mg) will be given from at  day of HCG injection and for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B(Cabergoline  group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>while in group B (Cabergoline  group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be givenat  day of HCG injection till 8 days and for 14 days .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diosmin</intervention_name>
    <description>2 tab / 8 hs Diosmin ( 500mg) will be given at  day of HCG injection till 8 days and for 14 days</description>
    <arm_group_label>Group A (Diosmin group)</arm_group_label>
    <other_name>Daflon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabergoline</intervention_name>
    <description>1 tab/day Cabergoline( 0.5 mg) will be given at  day of HCG injection till 8 days and for 14 days</description>
    <arm_group_label>Group B(Cabergoline  group)</arm_group_label>
    <other_name>Dostinex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: infertile women undergoing intracytoplasmic sperm injection or
        polycystic ovarin syndrome (PCO) with one of the following:

          1. Presence of more than 20 follicles by ultrasound

          2. E2 more than 3000 pg/ml

          3. Retrieval of more than 15 follicles

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>khalid mohamed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology, Benha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ahmed samy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology, Benha University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>khalid mohamed</last_name>
    <phone>201281469651</phone>
    <email>dr.khalidkhader77@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Benha univesity hospital</name>
      <address>
        <city>Benha</city>
        <state>El Qualyobia</state>
        <zip>13518</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>khalid mohamed</last_name>
      <phone>201281469651</phone>
      <email>dr.khalidkhader77@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>ahmed samy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>May 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>khalid abd aziz mohamed</investigator_full_name>
    <investigator_title>lecturer of ob/gyn</investigator_title>
  </responsible_party>
  <keyword>infertility</keyword>
  <keyword>ICSI</keyword>
  <keyword>OHSS</keyword>
  <keyword>Diosmin</keyword>
  <keyword>Cabergoline</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cabergoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
